GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Grifols SA (XMAD:GRF) » Definitions » Investments And Advances

Grifols (XMAD:GRF) Investments And Advances : €690 Mil (As of Sep. 2024)


View and export this data going back to 2006. Start your Free Trial

What is Grifols Investments And Advances?

Grifols's Investments And Advances for the quarter that ended in Sep. 2024 was €690 Mil.

Grifols's quarterly Investments And Advances declined from Dec. 2023 (€565 Mil) to Jun. 2024 (€560 Mil) but then increased from Jun. 2024 (€560 Mil) to Sep. 2024 (€690 Mil).

Grifols's annual Investments And Advances declined from Dec. 2022 (€2,430 Mil) to Dec. 2023 (€565 Mil) and declined from Dec. 2023 (€565 Mil) to Dec. 2024 (€529 Mil).


Grifols Investments And Advances Historical Data

The historical data trend for Grifols's Investments And Advances can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Grifols Investments And Advances Chart

Grifols Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Investments And Advances
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,980.06 2,263.11 2,429.92 565.11 528.97

Grifols Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Dec21 Jun22 Sep22 Dec22 Jun23 Sep23 Dec23 Jun24 Sep24 Dec24
Investments And Advances Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2,597.30 565.11 560.00 690.10 528.97

Grifols Investments And Advances Calculation

Investments And Advances includes all the non-current investments in affiliates, real estate, securities, etc.


Grifols Business Description

Address
Avinguda de la Generalitat, 152, Parc de Negocis Can Sant Joan, Sant Cugat del Valles, Barcelona, ESP, 08174
As a vertically integrated plasma derivative producer, Spain-based Grifols collects plasma and then manufactures and sells plasma-derived products globally. By acquiring Talecris in 2011, Grifols dramatically expanded its plasma-derived product portfolio, and following the firm's Biotest acquisition in April 2022, the biopharma business contributed 84% of sales in 2023. Grifols also has smaller segments including diagnostics (10% of sales) and biosupplies.